Skip to content

Trial Summary

A Randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Acronym:

ASCEND

ACTRN/NCT /ethics:

NCT05042128

Scientific title:

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)

Sponsor / Cooperative group:

Australasian Gastro-Intestinal Trials Group

Trial & Patient Characteristics

Cancer TypePancreas
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-04-13
Anticipated End Date2024-10-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6410
Principal InvestigatorProfessor Tim Price
Recruitment StatusNot Yet Recruiting